businessbriefs
Saved
Companies

Merck & Co.

George Merck · 1891

Merck & Co. did not invent modern pharma — it bought, merged, and outsourced its way into it.

Worth your time?3.5/5Yes.Study the whole thing.What works, what does not, who it is for ↓
10:09in productionCh. 1 · Expropriation, not entrepreneurship/ 10:09 · ceiling 15 min
4 chapters · 10:09Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.4 chapters · 1 min read · 10:09 planned

Read the brief

Merck & Co. is a multinational pharmaceutical company founded in 1891 as the American affiliate of the German Merck Group, made independent in 1919 after U.S. government expropriation and resale. Its early growth came from strategic mergers — not organic R&D — and its landmark streptomycin breakthrough relied on external academic research funded by the company. Under George W. Merck’s presidency (1925–1950), it developed synthetic vitamins, sulfas, antibiotics, and hormones, while simultaneously leading the U.S. biological weapons programme. The gap between its self-presentation as a scientific pioneer and its actual mechanics — acquisition, outsourcing, and state-aligned research — is the core of its business story.

CompaniesChemistryThe interwar yearsMedicineChemistry across the network →
Chapters & takeaways4
  1. 1:06
    Expropriation, not entrepreneurship

    Merck & Co. began as a foreign subsidiary — then became independent only after U.S. seizure and a $3.5 million auction buyback.

  2. 2:46
    Growth by acquisition

    Every major therapeutic capability before 1940 came via merger — quinine, vaccines, antitoxins — not internal R&D.

  3. 4:28
    Science on contract

    Streptomycin — its first blockbuster — was discovered in a Rutgers lab funded by Merck, not inside its own walls.

  4. 5:54
    Dual-use science

    Its interwar scientific output coexisted with direct leadership of the U.S. biological weapons programme — same executive, same era.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • shows how merger strategy built therapeutic capability
  • reveals the material conditions behind a 'scientific' reputation
What does not
  • establishes a self-sustaining R&D engine before the 1940s
  • proves that its scientific leadership was independent of state infrastructure
Study it if
  • historians of pharmaceutical industry structure
  • students of public–private research funding
Skip it if
  • founders seeking a 'disruption' playbook
  • investors assessing current valuation drivers
The written brief1 min read

What the company or idea is

Merck & Co. is a multinational pharmaceutical company founded in 1891 as the American affiliate of the German Merck Group, made independent in 1919 after U.S. government expropriation and resale.

How it actually makes money

Merck & Co. makes money by developing, manufacturing, and selling pharmaceuticals — including synthetic vitamins, sulfas, antibiotics like streptomycin, and hormones — and vaccines acquired via merger.

What works

Its merger strategy worked: acquiring Powers-Weightman-Rosengarten gave quinine capacity; the Sharp & Dohme–Mulford link brought vaccine technology used in WWI cavalry immunisation and diphtheria antitoxin delivery.

What does not

The company does not establish a continuous, self-contained R&D pipeline before the 1940s. Its major therapeutic breakthroughs relied on external academic partnerships (e.g., Rutgers) and wartime state programmes (e.g., War Research Service), not internal discovery engines.

What to take from it

Merck & Co.’s early growth came from strategic mergers (Powers-Weightman-Rosengarten, Sharp & Dohme), not organic scale — and its scientific reputation rests on funded external research and wartime state collaboration, not proprietary lab dominance.

Is it worth your time

Yes, if you are studying how pharmaceutical firms institutionalised R&D, leveraged government-linked research funding, or navigated wartime state contracts — not as a case of innovation heroism, but of structural alignment with U.S. scientific and military infrastructure.

Same desk · Companies4 of 325
10:30
AstraZeneca1913AstraZeneca is a Swedish–British multinational pharmaceutical and biotechnology company founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group. Its global headquarters are located in the Cambridge Biomedical Campus in Cambridge, England. It develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.
10:10
Roche1896Roche is a Swiss multinational holding healthcare company founded in 1896, headquartered in Basel, operating through Pharmaceuticals and Diagnostics divisions. It is the fifth-largest pharmaceutical company by revenue and the global leader in cancer treatments. It owns Genentech, Chugai Pharmaceuticals, Ventana, and Foundation Medicine as subsidiaries. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. In 2023, it ranked 76th in the Forbes Global 2000.
9:46
Bristol Myers Squibb1989Bristol Myers Squibb is not a story of scientific breakthrough but of industrial continuity: two 19th-century drugmakers merged in 1989, retained their WWII-era production logic, and now depend on seven high-revenue drugs sold overwhelmingly in one country.
11:20
Novartis1996Novartis is a Swiss multinational pharmaceutical corporation formed in 1996 by the merger of Ciba-Geigy and Sandoz. It operates as a publicly traded holding company with two main divisions — Innovative Medicines and Sandoz — and manufactures numerous branded drugs including clozapine, valsartan, imatinib mesylate, and cyclosporine. The merger combined the pharmaceutical and agrochemical divisions of the predecessor firms into an independent entity, and the company has since undergone extensive restructuring, acquisitions, divestitures, and spin-offs — including Alcon (spun off in 2019) and Sandoz (spun off in October 2023).
Up next in Business

Acquisition of Activision Blizzard by Microsoft

· 10:38

This wasn’t about Call of Duty — it was about owning the right to decide which games players pay for, where, and how often.

Next brief →Back to Companies
10:38